Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications

American Journal of Cardiology

Volumn 108, Issue 3 SUPPL., 2011, Pages 59B-67B

  Golden, Sherita Hill ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; METFORMIN; STATIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; FOLLOW UP; GLYCEMIC CONTROL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

EID: 79960972545     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.03.017     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, GA: CDC, 2008.
2. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM, for the Diabetes Prevention Program Research Group. Ten-year followup of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
4. UK Prospective Diabetes Study (UKPDS). Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, et al, for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, et al, for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. (Pubitemid 351831357)
7. Nathan DM, Clearly PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, for the DCCT/EDIC Study Research Group. Intensive diabetes control and cardiovascular disease in patients with type I diabetes. N Engl J Med 2005;353;2643-2653. (Pubitemid 41817713)
8. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(suppl 1):S11-S61.
9. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 2005;165:1910-1916. (Pubitemid 41352087)
10. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati F, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-431.
11. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006;29:877-882. (Pubitemid 44115310)
12. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Lancet Neurol 2005;4:821-826. (Pubitemid 41619437)
13. Golden SH, Selvin E, Cunningham EK. Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention. Diabetes Obes Metab 2007;9:792-798. (Pubitemid 47555202)
14. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al, for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
15. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, for the RECORD Study Group. Rosiglitazone evaluated for cardiac outcomes - an interim analysis. N Engl J Med 2007;357:28-38. (Pubitemid 47026732)
16. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, et al, on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
19. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, for the Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990.
20. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, et al, for the Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298.
21. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;1;51:394-403.
22. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419. (Pubitemid 30609443)
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
25. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
26. Golden SH, Munoz M. Pathophysiology and treatment of dyslipidemia in diabetes. In: Kwiterovitch P, ed. Johns Hopkins Textbook of Dyslipidemia. Philadelphia: Lippincott Williams & Wilkins, 2009:119-131.
27. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes. Part II. Incretin-based therapy and beyond. Circulation 2008;117:574-584.
28. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide- 12 receptor agoinsts and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. (Pubitemid 46048557)
29. McKennon SA, Campbell RK. The physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ 2007;33:55-67.
30. Fields AV, Patterson B, Karnik AA, Shannon RP. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol 2009 32:236-243.
31. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414.
32. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon- like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006 12:694-699. (Pubitemid 44881367)
33. Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug. Curr Atheroscler Rep 2009;11:93-99.
34. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008;40:593-606.
35. Fonseca VA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol 2011;107[suppl]:52B-58B.
36. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-624.
37. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel treatment trial. Lancet 2009;373:473-481.
38. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, and Colagiuri S, on behalf of the LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
39. Nauck MA, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, for the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32;84-90.
40. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, for the LEAD-4 Study Investigators. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230.
41. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, for the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5+met+SU): a randomized controlled trial. Diabetologia 2009;52:2046-2055.
42. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week, randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
43. GetGoal-M-As (Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin). [Clinical Trials.gov Website.] Available at: http://www.clinicaltrials.gov/ct2/show/NCT01169779? term=Lixisenatide&rank=2. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT01169779.
44. LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long-Term Evaluation. [Clinical Trials.gov Website.] Available at: http://clinicaltrials.gov/ct2/show/NCT01179048?term= LEADER&rank=3. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT01179048.
45. EXSCEL (Exenatide Study of Cardiovascular Event Lowering Trial: A Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus). [Clinical Trials.gov Website.] Available at: http://clinicaltrials.gov/ct2/show/NCT01144338. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT01144338.
46. TECOS (Sitagliptin Cardiovascular Outcome Study). [Clinical Trials.gov Website.] Available at: http://clinicaltrials.gov/ct2/show/NCT00790205. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT00790205.
47. SAVOR-TIMI 53 (Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications). [Clinical Trials.gov Website.] Available at: http://clinicaltrials.gov/ct2/show/NCT01107886?term= type+2+diabetes+mellitus+and+cardiovascular+disease&rank=37. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT01107886.
48. CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes). [Clinical Trials. gov Website.] Available at: http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=Linagliptin&rank= 12. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT01243424.
49. EXAMINE (Cardiovascular Outcomes Study of Alogliptin in Subjects with Type 2 Diabetes and Acute Coronary Syndrome). [Clinical Trials.gov Website.] Available at: http://clinicaltrials.gov/ct2/show/NCT00968708. Accessed March 4, 2011. Clinical Trials.gov Identifier NCT00968708.
50. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.
51. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, for the American Diabetes Association and the European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
52. US Dept of Health and Human Services. Healthy People 2020 topics and objectives: diabetes. [HealthyPeople.gov Website.] Available at: http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=8. Accessed November 30, 2010.